Question 1

Which countries lead Pericarditis and Cardiac Tamponade research?

Accepted Answer

By volume, the United States and China publish the most (1.3k and 369 works in 2022-now).

Question 2

Which institutions lead Pericarditis and Cardiac Tamponade research?

Accepted Answer

By volume in 2022-now, Cleveland Clinic publishes the most Pericarditis and Cardiac Tamponade research, followed by Mayo Clinic and All India Institute of Medical Sciences.

Question 3

Who are the leading researchers in Pericarditis and Cardiac Tamponade?

Accepted Answer

The most-cited researchers publishing on Pericarditis and Cardiac Tamponade include John J.V. McMurray, Emelia J. Benjamin and Stephan Windecker.

Question 4

Where is Pericarditis and Cardiac Tamponade research done?

Accepted Answer

The largest centres of Pericarditis and Cardiac Tamponade research in 2022-now are Cleveland (United States), New York (United States), Tokyo (Japan) and Beijing (China). Among places with at least 20 works in it, it is an unusually large share of all research in Cleveland.

Question 5

Where is the best place to study Pericarditis and Cardiac Tamponade?

Accepted Answer

Among universities, judged by research, University of Udine, Harvard University and Johns Hopkins University score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

Question 6

Is Pericarditis and Cardiac Tamponade research growing?

Accepted Answer

Output in 2022-2025 was 28% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Pericarditis and Cardiac Tamponade.

Question 7

What are the most cited papers in Pericarditis and Cardiac Tamponade?

Accepted Answer

The most cited paper in Pericarditis and Cardiac Tamponade is "Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases" (Alida L.P. Caforio et al., 2013), with 3,492 citations. Next come "Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction" (3,135) and "2015 ESC Guidelines for the diagnosis and management of pericardial diseases" (2,643).